个人简介
浙江杭州人，校聘副教授，日本金泽大学合作教授，医学博士，本科和硕士毕业于浙江工业大学，博士毕业于日本金泽大学医学部，2017年5月回校工作，主要从事生物活性成分和益生菌的安全评价与健康效应分析相关方面研究，具体包括：生物钟及其参与疾病发生的调控机制研究；肥胖、糖尿病和非酒精性脂肪肝等生活习惯病的发病机制研究及其预防和治疗；肠道菌群参与疾病调控的机制研究； 衰老的机制研究和抗衰老产品的开发；功能性食品的开发和功能评价；益生菌的开发和功能评价。主持省基金1项、省教育厅科研项目1项、企业横向合作项目2项，以核心参与人员参与国际及国内横向合作项目多项。以第一或第二导师指导博士研究生1名，硕士研究生8名，本科生10余人，指导本科生获全国大学生生命科学创新创业竞赛一等奖1项，二等奖3项，三等奖3项，获校级竞赛奖多项。截止目前，已申请专利8项，发表SCI论文40余篇，其中第一作者、共同第一作者、通讯作者近20篇，另有多篇论文投稿和返修中，ESI论文引用1000余次，个人H因子=16。
联系方式
Email：shali0145@zjut.edu.cn
代表性论文论著
1. Ma L, Ni Y*, Wang Z, Tu W, Ni L, Zhuge F, Zheng A, Hu L, Zhao Y, Zheng L, Fu Z*. Spermidine improves gut barrier integrity and gut microbiota function in diet-induced obese mice. Gut Microbes. 2020; DOI:10.1080/19490976.2020.1832857 (共一共通讯). IF=7.74
2. Ni Y, Ni L, Zhuge F, Fu Z*. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res. 2020; 64(17):e2000375. IF=5.309
3. Ni Y, Ni L, Zhuge F, Xu L, Fu Z*, Ota T*. Adipose Tissue Macrophage Phenotypes and Characteristics: The Key to Insulin Resistance in Obesity and Metabolic Disorders. Obesity (Silver Spring). 2020; 28(2):225-234 IF=3.742
4. Ni Y, Zhuge F, Nagashimada M, Nagata N, Xu L, Yamamoto S, Fuke N, Ushida Y, Suganuma H, Kaneko S, Ota T*. Lycopene prevents the progression of lipotoxicity-induced nonalcoholic steatohepatitis by decreasing oxidative stress in mice. Free Radic Biol Med. 2020; 152:571-582 IF=6.170
5. Ni Y, Wu L, Jiang J, Yang T, Wang Z, Ma L, Zheng L, Yang X, Wu Z, Fu Z*. Late-Night Eating-Induced Physiological Dysregulation and Circadian Misalignment Are Accompanied by Microbial Dysbiosis. Mol Nutr Food Res. 2019; 63(24): e1900867. IF=5.309
6. Ni Y, Yang X, Zheng L, Wang Z, Wu L, Jiang J, Yang T, Ma L, Fu Z*. Lactobacillus and Bifidobacterium Improves Physiological Function and Cognitive Ability in Aged Mice by the Regulation of Gut Microbiota. Mol Nutr Food Res. 2019; 63(22): e1900603. IF=5.309
7. Chen G, Ni Y, Nagata N, Zhuge F, Xu L, Nagashimada M, Yamamoto S, Ushida Y, Fuke N, Suganuma H, Kaneko S, Ota T*. Lycopene Alleviates Obesity-Induced Inflammation and Insulin Resistance by Regulating M1/M2 Status of Macrophages. Mol Nutr Food Res. 2019; 63(21): e1900602. (共同第一) IF=5.309
8. Chen G, Ni Y, Nagata N, Xu L, Zhuge F, Nagashimada M, Kaneko S, Ota T*. Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages. Lab Invest. 2019; 99(9):1335-1348. (共同第一) IF=4.197
9. Ni Y, Wang Z, Ma L, Yang L, Wu T, Fu Z*. Pilose antler polypeptides ameliorate inflammation and oxidative stress and improves gut microbiota in hypoxic-ischemic injured rats. Nutr Res. 2019; 64:93-108. IF=2.767
10. Ni Y, Ma L, Wu T, Lim AL, Zhang W, Yang L, Nakao Y, Fu Z*. The involvement of sympathetic nervous system in essence of chicken-facilitated physiological adaption and circadian resetting. Life Sci. 2018; 201: 54-62. IF=3.647
11. Ni Y, Wu T, Yang L, Xu Y, Ota T, Fu Z*. Protective effects of astaxanthin on a combination of D-galactose and jet lag-induced aging model in mice. Endocr J. 2018; 65(5):569-578. IF=1.952
12. Zhuge F, Ni Y, Nagashimada M, Nagata N, Xu L, Mukaida N, Kaneko S, Ota T*. DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization. Diabetes. 2016; 65(10):2966-79. IF=7.720
13. Ni Y, Zhuge F, Nagashimada M, Ota T*. Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis. Nutrients. 2016; 8(7). pii: E391. IF=4.546
14. Ni Y, Nagashimada M, Zhuge F, Zhan L, Nagata N, Tsutsui A, Nakanuma Y, Kaneko S, Ota T*. Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E. Sci Rep. 2015;5:17192. IF=3.998
15. Ni Y, Nagashimada M, Zhan L, Nagata N, Kobori M, Sugiura M, Ogawa K, Kaneko S, Ota T. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin. Endocrinology. 2015; 156(3):987-99. IF=3.934
发明专利
1. 倪银华,马灵燕,傅正伟. 亚精胺在制备治疗肠屏障功能受损药物中的应用.专利申请号: 201910207841.2
2. 倪银华,马灵燕,傅正伟. 亚精胺在制备减肥药物中的应用.专利申请号: 201910207846.5
3. 倪银华,马灵燕,傅正伟. 一种亚腈胺在制备治疗结肠炎药物中的应用.专利申请号: 201910913077.0
4. 倪银华,马灵燕,傅正伟. 一种亚腈胺在制备减少脂肪堆积制剂中的应用.专利申请号: 201911116284.X
5. 倪银华,马灵燕,傅正伟. 一种亚腈胺在制备治疗脂肪肝药物中的应用.专利申请号: 201911116244.5
6. 倪银华,马灵燕, 涂文清,傅正伟. 一种高效液相-质谱法检测亚精胺含量的方法.专利申请号: 201911365705.2
7. 倪银华,马灵燕,倪利阳,傅正伟. 一种亚精胺在制备提高毛螺菌属细菌丰度制剂中的应用. 专利申请号: 202010464899.8
8. 倪银华,马灵燕, 倪利阳,傅正伟. 一种亚精胺在制备肠道微生态调节剂中的应用.专利申请号: 202010464916.8
主要研究项目
1. 核受体Rev-erb通过调节肠道通透性改善非酒精性脂肪肝炎的机制研究
2. 益生菌延缓小鼠衰老的作用和机制研究
3. CMI-168/BEC对老年小鼠记忆和学习能力的调控作用研究